[6-K] Dr. Reddy's Laboratories Limited American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

On June 20, 2025, Dr. Reddy’s Laboratories Limited (NYSE: RDY) furnished a routine Form 6-K to the U.S. Securities and Exchange Commission. The filing affirms that the company continues to submit its annual reports on Form 20-F and is not relying on the Rule 12g3-2(b) exemption. The sole attachment is Exhibit 99.1 – “Intimation dated June 20, 2025.” The document was signed by Company Secretary K Randhir Singh. No financial statements, earnings figures, or descriptions of material transactions accompany this report, indicating that the submission is administrative in nature and unlikely to affect the company’s financial outlook or valuation.

Insights

Corporate Governance Expert

TL;DR: Routine 6-K, administrative only, no investor-relevant data.

The filing is a standard compliance submission required of foreign private issuers. It confirms Dr. Reddy’s continuing Form 20-F status, furnishes a single exhibit, and contains no operational, strategic, or financial disclosures. As such, it has neutral informational content and is unlikely to move the market. Investors should await more substantive filings, such as the next 20-F or earnings release, for actionable insights.

Portfolio Manager

TL;DR: No market impact; hold existing view on RDY.

From an investment standpoint, this 6-K offers no new metrics or forward-looking statements. The lack of earnings data, guidance, or corporate actions means the filing does not alter RDY’s risk-reward profile. Portfolio positioning should therefore remain based on previously available fundamentals—recent generics pipeline progress, balance-sheet strength, and sector trends—until more detailed disclosures emerge.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

June, 2025

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F   x                                  Form 40-F   ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes   ¨                                  No   x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

Exhibit Number		Description of Exhibits
99.1		Intimation dated June 20, 2025

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: June 20, 2025	By:	/s/ K Randhir Singh
		Name:	K Randhir Singh
		Title:	Company Secretary

3

FAQ

What did Dr. Reddy's Laboratories (RDY) file on June 20, 2025?

The company submitted a Form 6-K to the SEC, furnishing information for foreign private issuers.

Does the June 2025 6-K include financial or earnings data for RDY?

No. The filing contains no financial statements or earnings figures; it is purely administrative.

What is Exhibit 99.1 in RDY's latest 6-K?

Exhibit 99.1 is titled “Intimation dated June 20, 2025.” No further details are provided in the filing.

Under which form does Dr. Reddy's Laboratories file its annual reports?

The company files annual reports on Form 20-F.

Who signed the June 20, 2025 Form 6-K for Dr. Reddy's Laboratories?

The filing was signed by K Randhir Singh, Company Secretary.